← Back to Search

Other

ALY688 Ophthalmic Solution for Dry Eye Syndrome (OASIS-1 Trial)

Phase 2 & 3
Waitlist Available
Research Sponsored by Allysta Pharmaceutical
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks

Summary

This trial is testing ALY688 eye drops in two strengths (0.4% and 1%) to see if they are safe and effective for people with dry eye disease.

Eligible Conditions
  • Dry Eye Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Corneal fluorescein staining

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: ALY688 Ophthalmic Solution Concentration 2Experimental Treatment1 Intervention
Group II: ALY688 Ophthalmic Solution Concentration 1Experimental Treatment1 Intervention
Group III: Vehicle Ophthalmic SolutionPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALY688 Ophthalmic Solution
2021
Completed Phase 3
~930

Find a Location

Who is running the clinical trial?

Allysta PharmaceuticalLead Sponsor
3 Previous Clinical Trials
233 Total Patients Enrolled
~209 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top